Literature DB >> 3708559

Increased experimental metastatic capacity of a murine melanoma following induction of differentiation.

D C Bennett, T J Dexter, E J Ormerod, I R Hart.   

Abstract

Because of the interest in possible links between defective differentiation and cellular malignancy, the effects were examined of induced cell differentiation upon the experimental metastatic potential of the sublines F1 and F10 of the B16 mouse melanoma. These cell lines normally have low and high rates, respectively, of colonization of the lungs of mice after i.v. injection. Cellular differentiation was assessed by pigmentation and tyrosinase activity. In both cell lines, low and high levels of differentiation could reproducibly be generated by culture, respectively, at a low extracellular pH and at a higher pH in the presence of a melanocyte-stimulating hormone. Surprisingly, in both lines the cells grown under conditions promoting differentiation showed a markedly higher rate of experimental metastasis, despite their slower proliferation in culture and in subcutaneous tumor implants, than the poorly differentiated cells. Radiolabeled well- and poorly pigmented cells were not initially deposited at significantly different rates in the lungs of mice after i.v. injection. However, subsequent retention in the lungs fell more quickly for the poorly differentiated cells. As indicated by tests in vitro, this difference appears not to be due to differential cytotoxicity by either host macrophages or natural killer cells, and it is under further study.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3708559

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  20 in total

1.  Modulation of clonal progression in B16F1 melanoma cells.

Authors:  J F Harris; A F Chambers; A S Tam
Journal:  Clin Exp Metastasis       Date:  1991 Mar-Apr       Impact factor: 5.150

2.  Malignant properties of P635 glioma are independent of glial fibrillary acidic protein expression.

Authors:  A F Chambers; G H Denhardt; S M Wilson; J G Cairncross
Journal:  J Neurooncol       Date:  1991-08       Impact factor: 4.130

3.  msg1, a novel melanocyte-specific gene, encodes a nuclear protein and is associated with pigmentation.

Authors:  T Shioda; M H Fenner; K J Isselbacher
Journal:  Proc Natl Acad Sci U S A       Date:  1996-10-29       Impact factor: 11.205

4.  The regulation of cyclic AMP production and the role of cyclic AMP in B16 melanoma cells of differing metastatic potential.

Authors:  S E Hill; R C Rees; S MacNeil
Journal:  Clin Exp Metastasis       Date:  1990 Sep-Oct       Impact factor: 5.150

5.  N-methylformamide affects spontaneous metastases of 3LL lines and increases natural killer activity of tumor-bearing mice.

Authors:  C Greco; D Del Bufalo; D Giannarelli; M Marangolo; M P Fuggetta; E Bonmassar; G Zupi
Journal:  Clin Exp Metastasis       Date:  1990 Mar-Apr       Impact factor: 5.150

Review 6.  Leveraging melanocortin pathways to treat glomerular diseases.

Authors:  Rujun Gong
Journal:  Adv Chronic Kidney Dis       Date:  2014-03       Impact factor: 3.620

Review 7.  Sheep, wolf, or werewolf: cancer stem cells and the epithelial-to-mesenchymal transition.

Authors:  Jeffrey T Chang; Sendurai A Mani
Journal:  Cancer Lett       Date:  2013-03-14       Impact factor: 8.679

8.  Melanotropin receptors demonstrated in situ in human melanoma.

Authors:  J B Tatro; M Atkins; J W Mier; S Hardarson; H Wolfe; T Smith; M L Entwistle; S Reichlin
Journal:  J Clin Invest       Date:  1990-06       Impact factor: 14.808

Review 9.  Modulation of tumor cell gene expression and phenotype by the organ-specific metastatic environment.

Authors:  R Radinsky
Journal:  Cancer Metastasis Rev       Date:  1995-12       Impact factor: 9.264

10.  Enhancement of pulmonary metastasis formation and gamma-glutamyltranspeptidase activity in B16 melanoma induced by differentiation in vitro.

Authors:  J A Prezioso; N Wang; L Duty; W D Bloomer; E Gorelik
Journal:  Clin Exp Metastasis       Date:  1993-05       Impact factor: 5.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.